CS-230success
Zentiva Group, Prague-based European generic and over-the-counter medicines company, carved out of Sanofi in 2018 and owned by Advent International until 2026
Carve-out of Sanofi's European generics business as an independent company in 2018, followed by a standalone build-out under private equity ownership: acquisitions of commercial businesses and manufacturing sites, entry into new Central and Eastern European markets, and investment in production, ending with a sale to GTCR in 2026
- Region
- Central and Eastern Europe, Western Europe
- Country
- Czech Republic, Romania, France, United Kingdom, India
- Industry
- Pharmaceuticals and Life Sciences (Chemicals and Process Manufacturing)
- Functions
- Strategy, Corporate Development & Transformation Office, Manufacturing & Production, Sales & Revenue Operations, Supply Chain & Logistics
- Topics
- Revenue growth has stalled; M&A integration or corporate complexity is destroying value; Investment capital is not generating returns
- Starting situation
- New initiative
- Period
- 2018–2026
- Last verified
- 5 November 2026
Executive summary
In 2018 Sanofi sold Zentiva, its European generics business based in Prague, to the private equity firm Advent for an enterprise value of €1.9bn, as part of simplifying its own portfolio [C01]. The deal closed ahead of schedule, and Zentiva began operating as an independent company on 1 October 2018 with more than 2,500 people and two plants [C01, C04].
Advent set out to build an independent European generics leader [C02]. Over the next seven years Zentiva bought commercial businesses in Romania and the UK, a plant in India and Alvogen's business in 14 Central and Eastern European markets, and invested in its plants in Prague and Bucharest [C05, C06, C07]. By 2026 it had more than 5,400 employees, four manufacturing sites and customers in more than 40 countries [C12].
Advent, the seller, said revenue and EBITDA had more than doubled, and it sold Zentiva to GTCR in a deal reported at €4.1bn [C09, C10]. The case shows how a non-core unit of a large group can be turned into a standalone company through a clean separation followed by targeted acquisitions. Because Zentiva is private, the financial evidence rests largely on the owners' own statements.
Outcome: success
The stated objectives were reported met, and the outcome was not later reversed by a write-down, exit or abandonment attributable to the initiative.
Basis of the outcome
Stated aims at the carve-out: Advent said it aimed to build a new, independent European generics leader (S04), and Zentiva said it would expand its footprint in generics and over-the-counter medicines across Europe (S06, S07). No dated targets were found in the sources read. Reported results: Sanofi completed the sale ahead of schedule, effective 30 September 2018, and Zentiva operated independently from 1 October 2018 (S01, S02, S06); Zentiva bought Solacium in Romania, Creo Pharma in the UK, a manufacturing site in Ankleshwar, India, and Alvogen's business in 14 Central and Eastern European markets with more than 1,000 staff and a Bucharest plant (S08, S09, S10); employees rose from more than 2,500 in 2018 to more than 5,400 in 2026, countries served from 25 to more than 40, and wholly owned manufacturing sites from two to four (S05, S06, S14, S15); Advent, the seller, said when it announced the sale that Zentiva's revenue and EBITDA had more than doubled during its ownership; no company-filed or independent revenue or EBITDA figure was found (S13, S14); and Advent sold Zentiva to GTCR in a deal reported by the Financial Times at €4.1bn, against the €1.9bn enterprise value of 2018, completed on 9 April 2026 (S01, S12, S15). Limits stated plainly: revenue and EBITDA figures were not disclosed, so the doubling rests on the seller's own statement and is not independently confirmed; much of the growth came through acquisitions; and the sale values compare an enterprise value in 2018 with a reported deal value in 2025.
Key figures
| Phase | Figure | Value | When | Verification |
|---|---|---|---|---|
| Before | Enterprise value paid by Advent | €1.9bn | 2018 | company_reported |
| Before | Employees at independence | more than 2,500 | Oct 2018 | company_reported |
| During | Markets added or strengthened by the Alvogen deal | 14 | 2020 | company_reported |
| After | Employees | more than 5,400 | Apr 2026 | company_reported |
| After | Reported value of the sale to GTCR | €4.1bn | Sep 2025 | press_reported |
- company_reported
- A company statement, press release or investor presentation that no one has independently checked.
- press_reported
- A journalist's own reporting.
Practices this case bears on
- SupportsWhen the thesis has failed, exit in one decisive move and say what is kept BP-007
- SupportsChoose the integration model from where the deal's value sits, and retain the people who hold it BP-008
- SupportsTie every benefit to the financial statements, bank it before counting it, and keep tracking after the programme ends BP-010
- MixedTreat vendor attestations, awards and executive testimony as claims to test, not as assurance BP-019
- SupportsBuild succession into the transformation, not after it BP-020
- SupportsState one short plan, repeat it, and run it through one small forum on a fixed cadence BP-028
- SupportsRenew the leadership team quickly, choosing leaders from where the business is going BP-029
- SupportsReorganise around the new business and the units that face customers, before the transition, not after BP-030
- SupportsSeparate the programme's own effect from tailwinds, shocks and one-off gains before claiming credit BP-035
- MixedSeparate the programme's own effect from tailwinds, shocks and one-off gains before claiming credit BP-035
- SupportsDivest what does not fit the core by a stated criterion, including prestige and profitable businesses BP-050
- SupportsBuy the capabilities the new strategy lacks rather than building all of them BP-053
- SupportsMap critical dependencies several tiers deep, buffer what cannot be re-sourced, and decide who pays for resilience BP-064
- SupportsBuild the enabling architecture and infrastructure before the applications that depend on it BP-071
Sources
- S01 Sanofi completes divestiture of Zentiva to Advent · not stated, Sanofi, 2018-10-01 · accessed 2026-11-05
- S02 Sanofi completes divestiture of Zentiva to Advent (Form 6-K, Exhibit 99.1) · Sanofi, U.S. Securities and Exchange Commission (filed by Sanofi), 2018-10-01 · accessed 2026-11-05
- S03 Sanofi completes divestiture of Zentiva to Advent (Hong Kong copy) · not stated, Sanofi, 2018-10-01 · accessed 2026-11-05
- S04 Acquisition of Sanofi's Zentiva completed by Advent International · not stated, BioPharm International, 2018-10 · accessed 2026-11-05
- S05 Sanofi completes $2.2 billion divestiture of European generics biz to Advent · not stated, DCAT Value Chain Insights, 2018-10-05 · accessed 2026-11-05
- S06 Generics manufacturer Zentiva starts operations as independent company · not stated, Zentiva, 2018-09-30 · accessed 2026-11-05
- S07 Generics manufacturer Zentiva becomes an independent organization · not stated, News-Medical, 2018-10-03 · accessed 2026-11-05
- S08 Zentiva buys Romanian pharmaceutical producer · not stated, Romania Insider, 2019-03-14 · accessed 2026-11-05
- S09 Zentiva buys Alvogen business · not stated, Pharmaceutical Technology, 2019-10-28 · accessed 2026-11-05
- S10 Zentiva extends commercial footprint by completing acquisition of CEE business from Alvogen · not stated, Zentiva, 2020-04-07 · accessed 2026-11-05
- S11 US PE firms, Aurobindo said to eye Zentiva in €5 billion deal · not stated, Bloomberg Law, 2025-07-24 · accessed 2026-11-05
- S12 Advent to sell Zentiva to private equity GTCR in USD 4.8 billion deal, closing expected in 2026 · not stated, Medical Dialogues, 2025-09-12 · accessed 2026-11-05
- S13 Advent to sell generic drugmaker Zentiva to GTCR · IPP Bureau, Indian Pharma Post, 2025-09-16 · accessed 2026-11-05
- S14 Zentiva announces sale from Advent to GTCR · not stated, Zentiva, 2025-09-11 · accessed 2026-11-05
- S15 GTCR completes acquisition of Zentiva, a leading European generics pharmaceutical company · GTCR and Zentiva, BioSpace (PR Newswire), 2026-04-09 · accessed 2026-11-05
Researched and fact-checked knowledgebase · Knowledgebase built 5 November 2026 · Last verified 5 November 2026
Practices, their evidence grades and case summaries are public. Full case studies are available in AXIOM to subscribers and AXIOM Discover participants.

